These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17612707)

  • 1. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
    Wesnes K
    Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivastigmine for dementia associated with Parkinson's disease.
    Harada CN; Shega JW; Sachs GA
    N Engl J Med; 2005 Mar; 352(13):1387; author reply 1387. PubMed ID: 15800242
    [No Abstract]   [Full Text] [Related]  

  • 4. Cholinesterase inhibitors for Parkinson's disease dementia.
    Maidment I; Fox C; Boustani M
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine in Parkinson's disease dementia.
    Chitnis S; Rao J
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivastigmine: in Parkinson's disease dementia.
    Siddiqui MA; Wagstaff AJ
    CNS Drugs; 2006; 20(9):739-47; discussion 748-50. PubMed ID: 16953649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.
    Oertel W; Poewe W; Wolters E; De Deyn PP; Emre M; Kirsch C; Hsu C; Tekin S; Lane R
    Drug Saf; 2008; 31(1):79-94. PubMed ID: 18095748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivastigmine and Parkinson dementia complex.
    Moretti R; Torre P; Vilotti C; Antonello RM; Pizzolato G
    Expert Opin Pharmacother; 2007 Apr; 8(6):817-29. PubMed ID: 17425477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine for dementia associated with Parkinson's disease.
    Morgan J; Sethi KD
    Curr Neurol Neurosci Rep; 2005 Jul; 5(4):263-5. PubMed ID: 15987609
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
    Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
    Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.
    Olin JT; Aarsland D; Meng X
    Dement Geriatr Cogn Disord; 2010; 29(6):510-5. PubMed ID: 20523050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rivastigmine against dementia in Parkinson disease?].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2007 Nov; 127(22):2973; author reply 2973-4. PubMed ID: 18026256
    [No Abstract]   [Full Text] [Related]  

  • 19. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
    Bullock R; Cameron A
    Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
    Cummings J; Winblad B
    Expert Rev Neurother; 2007 Nov; 7(11):1457-63. PubMed ID: 17997695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.